Distributing since 1889 • Employee Owned for Better Service
Your 1st Choice!
Sign In
Quick Search:

Shopping Cart Cart |  My Account |  View Printable Page Print
Product Detail

Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Consensus Study Report

NAP
Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Consensus Study Report Cover Image
Pricing & Availability
Available: 1
List Price:$90.00

Email this title to a friend Email this title to a friend
Printer friendly version Printer friendly version

Other formats:
Book Information
Edition: 1st
Publisher: National Academies Press
ISBN: 0-309-67210-4 (0309672104)
ISBN-13: 978-0-309-67210-8 (9780309672108)
Binding: Softcover
Copyright: 2020
Publish Date: 04/20
Weight: 1.48 Lbs.
Pages: 407
Subject Class: PRM (Pharmacology)
Return Policy: Returns accepted up to 18 months
 
Class Specifications
Abstract: Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors. At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events.

Follow Matthews Book Co. on:
Follow Matthews Book Co. on Twitter

Copyright © 2001-2020 Matthews Book Company - All rights reserved. - 11559 Rock Island Ct., Maryland Heights, MO, 63043 - (800) MED-BOOK
Matthews Privacy Statement